Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Revised October 2020
This report, revised in October 2020, is the third of a series of investigations into Enbrel, an arthritis medication marketed by biopharmaceutical company Amgen in the U.S. It includes figures on the patent applications and spending for Enbrel in the U.S. compared to other regions, as well as the impact of overpatenting on patients and families.
We provide information on industries, companies, consumers, trends, countries, and politics, covering the latest and most important issues in a condensed format.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)